News for Catalyst Pharmaceuticals, Inc. (CPRX)

Total Revenue (2024): $491.7 million, a 23.5% increase year over year.Net Product Revenue (2024): $489.3 million, a 23.4% increase over 2023.Q4 2024 Total Reve

Strengths highlight Catalyst Pharmaceuticals Inc's unique product offerings and market penetration.Weaknesses and challenges underscore the need for strategic

Feb 27, 2025 / 01:30PM GMTOperator Greetings and welcome to the Catalyst Pharmaceuticals fourth quarter in full year 2024 financial results conference call. (Op

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsMichael Kalb - Executive Vice...

Catalyst Pharmaceuticals Inc (CPRX) announced its financial results for the fourth quarter and full year of 2024, reporting a record total revenue of $491.7 mil

Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Stro

**media[551543]**

Catalyst Pharmaceuticals' Q4 results beat estimates with $0.70 EPS & $141.8M revenue. 2025 forecast: $545M-$565M driven by FIRDAPSE & AGAMREE growth.

Catalyst Pharmaceuticals Inc (CPRX) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $134.20 million, and t

Catalyst Pharmaceuticals Inc (CPRX) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $134.20 million, and t

Catalyst Pharmaceuticals Inc (CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has announced that it wi

The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharm

**media[538768]**

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

**media[522514]**

Catalyst Pharmaceuticals Inc (CPRX), a commercial-stage biopharmaceutical company, announced on January 21, 2025, that its sub-licensee in Japan, DyDo Pharma, I

**media[520516]**

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE ® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on January 8. Read why I rate CPRX stock as a Strong Buy.